[关键词]
[摘要]
目的:通过对比玻璃体腔注射抗血管内皮生长因子(VEGF)药物中心(简称玻璃体腔注药中心)成立前后患者在疗程跨度、治疗频次、医生连续性的变化,系统评估该管理模式对慢病眼底病治疗的临床实效性。
方法:回顾性研究。收集2023年1月1日至2024年12月31日于西安市人民医院初始接受抗VEGF药物治疗的眼底疾病患者。将2023年玻璃体腔注药中心成立前接受治疗的患者设为对照组,2024年玻璃体腔注药中心成立后接受治疗的患者设为观察组。对比观察组与对照组的整体平均针数,体系留存时间; 对比常见慢性眼病的观察组与对照组平均注射针数、注射医生更换频率与完成3针负荷期治疗的比例。
结果:共纳入13 792例13 792眼,观察组7 660眼,其中男4 121例,女3 539例,平均年龄58.70±14.39岁; 对照组6 132眼,其中男3 358例,女2 774例,平均年龄58.11±14.74岁; 体系留存时间观察组显著长于对照组(P<0.001)。按疾病分类后,观察组中糖尿病黄斑水肿(DME)、渗出型年龄相关性黄斑变性(wARMD)、视网膜静脉阻塞继发黄斑水肿(RVO-ME)患者的平均注射针数、体系留存时间、注射医生更换频率均显著高于对照组(均P<0.05)。且三种疾病观察组患者完成3针负荷期治疗比例均高于对照组(均P<0.05)。
结论:玻璃体腔注药中心的建立扩大了服务规模,延长了患者体系留存时间,并提高了抗VEGF规范3针负荷期治疗的完成率。
[Key word]
[Abstract]
AIM: To compare the changes in treatment duration, treatment frequency and physician continuity in patients before and after the establishment of the anti-vascular endothelial growth factor(VEGF)intravitreal injection center(hereafter the intravitreal injection center), and to systematically assess the clinical effectiveness of this management model for chronic fundus diseases.
METHODS: This was a retrospective study.The study included patients with fundus diseases who initially received anti-VEGF therapy at Xi'an People's Hospital between January 1, 2023, and December 31, 2024. Patients receiving treatment before the establishment of the intravitreal injection center in 2023 were assigned to the control group, while those treated after the center's establishment in 2024 were assigned to the observation group. The study compared the overall average number of injections and system retention time between the observation group and the control group. For common chronic ocular diseases, the mean number of injections, frequency of physician turnover, and proportion of patients completing the 3-injection loading phase were compared between the observation and control groups.
RESULTS: A total of 13 792 patients(13 792 eyes)were enrolled. The observation group included 7 660 eyes(4 121 males and 3 539 females), with a mean age of 58.70±14.39 y. The control group included 6 132 eyes(3 358 males and 2 774 females), with a mean age of 58.11±14.74 y. The duration of drug retention was significantly longer in the observation group than in the control group(P<0.001). After classification by disease, patients with diabetic macular edema(DME), wet age-related macular degeneration(wARMD), and retinal vein occlusion-associated macular edema(RVO-ME)in the observation group had significantly higher average numbers of injections, longer system retention times, and higher frequencies of physician changes compared to the control group(all P<0.05). Furthermore, the proportion of patients in the observation group with all three conditions who completed the 3-injection loading phase was higher than that in the control group(all P<0.05).
CONCLUSION: The establishment of the intravitreal injection center has expanded the scope of services, prolonged patient retention in the care program, and improved the completion rate of the standard 3-injection loading phase of anti-VEGF therapy.
[中图分类号]
[基金项目]